Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
- 28 December 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (1), 677-694
- https://doi.org/10.1021/acs.jmedchem.0c01698
Abstract
A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis, began with a survey of six-membered heteroaryl groups in place of the N-methyl triazolyl moiety in 6. The X-ray co-crystal structure of an early lead (12) revealed a potential new binding pocket. Exploration of the new pocket resulted in two frontrunners for a clinical candidate. The potential hydrogen bonding interaction with Thr599 in the pocket was achieved with a tertiary amide moiety, confirmed by the X-ray co-crystal structure of 29. When the diversity search was extended to nicotinamides, a single fluorine atom addition was found to significantly enhance the permeability, which directly led to the discovery of 7 (BMS-986202) as a clinical Tyk2 inhibitor that binds to Tyk2 JH2. The preclinical studies of 7, including efficacy studies in mouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus, will also be presented.Keywords
This publication has 47 references indexed in Scilit:
- A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective InhibitorsThe Journal of Immunology, 2013
- Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617FNature Structural & Molecular Biology, 2012
- Interferon Alpha in Systemic Lupus ErythematosusJournal of Biomedicine and Biotechnology, 2010
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritisClinical and Experimental Immunology, 2008
- TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutationsLeukemia, 2007
- Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin ABritish Journal of Dermatology, 2006
- Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23Experimental Dermatology, 2004
- Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis VulgarisThe Journal of Experimental Medicine, 2004
- Expression of Interleukin-12 is Increased in Psoriatic SkinJournal of Investigative Dermatology, 1998